{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T08:31:02Z","timestamp":1794126662386,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw, The Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","award":["200320017"],"award-info":[{"award-number":["200320017"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12916-017-0988-0","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T09:39:26Z","timestamp":1515577166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice \u2013 the ECSTATIC study: a cluster randomised non-inferiority trial"],"prefix":"10.1186","volume":"16","author":[{"given":"Clare H.","family":"Luymes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinde K. E.","family":"Poortvliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"van Geloven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot W. M.","family":"de Waal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M.","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanet W.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem J. J.","family":"Assendelft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert B.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"de Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattijs E.","family":"Numans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"key":"988_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators: Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117\u201371.","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"988_CR2","volume-title":"Hart- en vaatziekten in Nederland 2010. Cijfers over leefstijl- en risicofactoren, ziekte en sterfte","author":"I Vaartjes","year":"2011","unstructured":"Vaartjes I, van Dis I, Visseren FLI, Bots ML. Hart- en vaatziekten in Nederland 2010. Cijfers over leefstijl- en risicofactoren, ziekte en sterfte. Den Haag: Nederlandse Hartstichting; 2011."},{"key":"988_CR3","doi-asserted-by":"crossref","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315\u201381.","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"988_CR4","first-page":"A5104","volume":"156","author":"T Wiersma","year":"2012","unstructured":"Wiersma T, Smulders YM, Stehouwer CD, Konings KT, Lanphen J. Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011). Ned Tijdschr Geneeskd. 2012;156:A5104.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"988_CR5","unstructured":"Gohlke H, Gielen S, K\u00f6nig W, Schuler G, Rauch B, Sonntag F. ESC Pocket Guidelines Pr\u00e4vention von Herz-Kreislauf-Erkrankungen. D\u00fcsseldorf: Deutsche Gesellschaft f\u00fcr Kardiologie - Herz- un Kreislauf Forschung eV (DGK); 2012. 31 p. http:\/\/leitlinien.dgk.org\/files\/PL_Pr%C3%A4vention_Internet_13.pdf . Accessed 25 Sep 2017."},{"key":"988_CR6","volume-title":"Guide to management of hypertension 2008. Updated December 2010","author":"National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee)","year":"2010","unstructured":"National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated December 2010. Canberra: Heart Foundation; 2010. http:\/\/heartfoundation.org.au\/images\/uploads\/publications\/HypertensionGuidelines2008to2010Update.pdf . Accessed 25 Sep 2017."},{"key":"988_CR7","volume-title":"New Zealand primary care handbook 2012","author":"Cardiovascular Disease Risk Assessment Steering Group","year":"2013","unstructured":"Cardiovascular Disease Risk Assessment Steering Group. New Zealand primary care handbook 2012. Wellington: Ministry of Health; 2013. https:\/\/www.health.govt.nz\/system\/files\/documents\/publications\/cardiovascular-disease-risk-assessment-updated-2013-dec13.pdf , Accessed 25 Sep 2017."},{"key":"988_CR8","first-page":"435","volume":"46","author":"E Walma","year":"2003","unstructured":"Walma E, Thomas S, Prins A, Grundmeijer H, Van der Laan J, Wiersma T. NHG-standaard hypertensie. Huisarts en Wetenschap. 2003;46:435\u201349.","journal-title":"Huisarts en Wetenschap"},{"key":"988_CR9","volume-title":"NHG-standaard cholesterol","author":"S Thomas","year":"1999","unstructured":"Thomas S, van der Weijden T, van Drenth B, Haverkort A, Hooi J, van der Laan J. NHG-standaard cholesterol. Utrecht: Nederlands Huisartsen Genootschap; 1999."},{"key":"988_CR10","unstructured":"\u00c4rztliche Zentralstelle Qualit\u00e4tssicherung. Leitlinien-Clearing-Bericht \u201cHypertonie\u201d. K\u00f6ln: \u00c4rztliche Zentralstelle Qualit\u00e4tssicherung; 2000. http:\/\/www.leitlinien.de\/mdb\/edocs\/pdf\/schriftenreihe\/schriftenreihe5.pdf . Accessed 25 Sep 2017."},{"key":"988_CR11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/13814788.2015.1064389","volume":"21","author":"CH Luymes","year":"2015","unstructured":"Luymes CH, de Ruijter W, Poortvliet RK, Putter H, van Duijn HJ, Numans ME, et al. Change in calculated cardiovascular risk due to guideline revision: a cross-sectional study in the Netherlands. Eur J Gen Pract. 2015;21:217\u201323.","journal-title":"Eur J Gen Pract"},{"key":"988_CR12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3399\/bjgp11X578025","volume":"61","author":"HJ Duijn van","year":"2011","unstructured":"van Duijn HJ, Belo JN, Blom JW, Velberg ID, Assendelft WJ. Revised guidelines for cardiovascular risk management \u2013 time to stop medication? a practice-based intervention study. Br J Gen Pract. 2011;61:347\u201352.","journal-title":"Br J Gen Pract"},{"key":"988_CR13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bcp.12161","volume":"77","author":"C Cahir","year":"2014","unstructured":"Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77:201\u201310.","journal-title":"Br J Clin Pharmacol"},{"key":"988_CR14","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1001\/archinte.1991.00400090107019","volume":"151","author":"MH Beers","year":"1991","unstructured":"Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151:1825\u201332.","journal-title":"Arch Intern Med"},{"key":"988_CR15","doi-asserted-by":"crossref","first-page":"e006544","DOI":"10.1136\/bmjopen-2014-006544","volume":"4","author":"K Anderson","year":"2014","unstructured":"Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4:e006544.","journal-title":"BMJ Open"},{"key":"988_CR16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jclinepi.2008.07.010","volume":"62","author":"R Schellings","year":"2009","unstructured":"Schellings R, Kessels AG, ter Riet G, Sturmans F, Widdershoven GA, Knottnerus JA. Indications and requirements for the use of prerandomization. J Clin Epidemiol. 2009;62:393\u20139.","journal-title":"J Clin Epidemiol"},{"key":"988_CR17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/1060028016637181","volume":"50","author":"CH Luymes","year":"2016","unstructured":"Luymes CH, van der Kleij RM, Poortvliet RK, de Ruijter W, Reis R, Numans ME. Deprescribing potentially inappropriate preventive cardiovascular medication: barriers and enablers for patients and general practitioners. Ann Pharmacother. 2016;50:446\u201354.","journal-title":"Ann Pharmacother"},{"key":"988_CR18","doi-asserted-by":"crossref","first-page":"f7450","DOI":"10.1136\/bmj.f7450","volume":"348","author":"RL Grant","year":"2014","unstructured":"Grant RL. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ. 2014;348:f7450.","journal-title":"BMJ"},{"key":"988_CR19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.15288\/jsa.1992.53.476","volume":"53","author":"P Lemmens","year":"1992","unstructured":"Lemmens P, Tan ES, Knibbe RA. Measuring quantity and frequency of drinking in a general population survey: a comparison of five indices. J Stud Alcohol. 1992;53:476\u201386.","journal-title":"J Stud Alcohol"},{"key":"988_CR20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0895-4356(03)00220-8","volume":"56","author":"GC Wendel-Vos","year":"2003","unstructured":"Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56:1163\u20139.","journal-title":"J Clin Epidemiol"},{"key":"988_CR21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1249\/00005768-199301000-00011","volume":"25","author":"BE Ainsworth","year":"1993","unstructured":"Ainsworth BE, Haskell WL, Leon AS, Jacobs Jr DR, Montoye HJ, Sallis JF, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;25:71\u201380.","journal-title":"Med Sci Sports Exerc"},{"key":"988_CR22","first-page":"180","volume":"78","author":"H Kemper","year":"2000","unstructured":"Kemper H, Ooijendijk W, Stiggelbout M. FORUM-consensus over de nederlandse norm voor gezond bewegen. TSG-Tijdschrift voor Gezondheidswetenschappen. 2000;78:180\u20133.","journal-title":"TSG-Tijdschrift voor Gezondheidswetenschappen"},{"key":"988_CR23","unstructured":"Brink CLvd, Ock\u00e9 MC, Houben AW, Nierop Pv, Droomers M. Validering van standaardvraagstelling voeding voor Lokale en Nationale Monitor Volksgezondheid, RIVM rapport 260854008\/2005. 2005. http:\/\/www.rivm.nl\/dsresource?objectid=e370650a-dd54-4ccc-b4f1-1f26c0494215&type=org&disposition=inline . Accessed 25 Sep 2017."},{"key":"988_CR24","volume-title":"Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg","author":"Z Nederland","year":"2015","unstructured":"Nederland Z. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Diemen: Zorginstituut Nederland; 2015. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg , Accessed 25 Sep 2017."},{"key":"988_CR25","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hec.1124","volume":"15","author":"LM Lamers","year":"2006","unstructured":"Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ. The Dutch tariff: results and arguments for an effective design for national EQ\u20105D valuation studies. Health Econ. 2006;15:1121\u201332.","journal-title":"Health Econ"},{"key":"988_CR26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00019053-200321010-00003","volume":"21","author":"N Zethraeus","year":"2003","unstructured":"Zethraeus N, Johannesson M, J\u00f6nsson B, L\u00f6thgren M, Tambour M. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics. 2003;21:39\u201348.","journal-title":"Pharmacoeconomics"},{"key":"988_CR27","unstructured":"ICH Steering Committee. Harmonised Tripartite Guideline: Choice of Control Group and Related Issues in Clinical Trials (E10). Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2000. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E10\/Step4\/E10_Guideline.pdf ."},{"key":"988_CR28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D'Agostino","year":"2003","unstructured":"D'Agostino RB, Massaro JM, Sullivan LM. Non\u2010inferiority trials: design concepts and issues \u2013 the encounters of academic consultants in statistics. Stat Med. 2003;22:169\u201386.","journal-title":"Stat Med"},{"key":"988_CR29","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/10705510802339072","volume":"15","author":"TE Bodner","year":"2008","unstructured":"Bodner TE. What improves with increased missing data imputations? Struct Equ Model. 2008;15:651\u201375.","journal-title":"Struct Equ Model"},{"key":"988_CR30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s13063-015-0919-3","volume":"16","author":"L Thabane","year":"2015","unstructured":"Thabane L, Kaczorowski J, Dolovich L, Chambers LW, Mbuagbaw L. Reducing the confusion and controversies around pragmatic trials: using the cardiovascular health awareness program (CHAP) trial as an illustrative example. Trials. 2015;16:387.","journal-title":"Trials"},{"key":"988_CR31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","volume":"165","author":"RH Chapman","year":"2005","unstructured":"Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147\u201352.","journal-title":"Arch Intern Med"},{"key":"988_CR32","doi-asserted-by":"crossref","first-page":"e106455","DOI":"10.1371\/journal.pone.0106455","volume":"9","author":"T-P Staa van","year":"2014","unstructured":"van Staa T-P, Gulliford M, Ng ES-W, Goldacre B, Smeeth L. Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk? PLoS One. 2014;9:e106455.","journal-title":"PLoS One"},{"key":"988_CR33","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnson E, Bor\u00e9n J, Mardinoglu A. Personalized cardiovascular disease prediction and treatment \u2013 a review of existing strategies and novel systems medicine tools. Front Physiol. 2016;7:2.","DOI":"10.3389\/fphys.2016.00002"},{"key":"988_CR34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/hrt.2010.220442","volume":"97","author":"SM Liew","year":"2011","unstructured":"Liew SM, Doust J, Glasziou P. Cardiovascular risk scores do not account for the effect of treatment: a review. Heart. 2011;97:689\u201397.","journal-title":"Heart"},{"key":"988_CR35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"Cholesterol Treatment Trialists' (CTT) Collaborators","year":"2012","unstructured":"Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390.","journal-title":"Lancet"},{"key":"988_CR36","doi-asserted-by":"crossref","unstructured":"Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.","DOI":"10.1002\/14651858.CD004816.pub5"},{"key":"988_CR37","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","volume":"374","author":"EM Lonn","year":"2016","unstructured":"Lonn EM, Bosch J, L\u00f3pez-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009\u201320.","journal-title":"N Engl J Med"},{"key":"988_CR38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"988_CR39","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","volume":"170","author":"KK Ray","year":"2010","unstructured":"Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med. 2010;170:1024\u201331.","journal-title":"Arch Intern Med"},{"key":"988_CR40","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca F, Genest J, Gotto Jr AM, Kastelein J, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195.","journal-title":"N Engl J Med"},{"key":"988_CR41","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S, Lonn E, Pais P, Bosch J, L\u00f3pez-Jaramillo P, Zhu J, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374:2032\u201343.","journal-title":"N Engl J Med"},{"key":"988_CR42","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021\u201331.","journal-title":"N Engl J Med"},{"key":"988_CR43","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"2015","author":"The SPRINT Research Group","year":"2015","unstructured":"The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;2015:2103\u201316.","journal-title":"N Engl J Med"},{"key":"988_CR44","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","volume":"368","author":"H Nakamura","year":"2006","unstructured":"Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155\u201363.","journal-title":"Lancet"},{"key":"988_CR45","doi-asserted-by":"crossref","first-page":"e1001361","DOI":"10.1371\/journal.pmed.1001361","volume":"9","author":"BS Ferket","year":"2012","unstructured":"Ferket BS, van Kempen BJ, Heeringa J, Spronk S, Fleischmann KE, Nijhuis RL, et al. Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study. PLoS Med. 2012;9:e1001361.","journal-title":"PLoS Med"},{"key":"988_CR46","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/PPA.S131625","volume":"11","author":"CH Luymes","year":"2017","unstructured":"Luymes CH, Boelhouwer NJ, Poortvliet RK, de Ruijter W, Reis R, Numans ME. Understanding deprescribing of preventive cardiovascular medication: a Q-methodology study in patients. Patient Prefer Adherence. 2017;11:975\u201384.","journal-title":"Patient Prefer Adherence"},{"key":"988_CR47","doi-asserted-by":"crossref","unstructured":"Hartley L, Igbinedion E, Holmes J, Flowers N, Thorogood M, Clarke A, et al. Increased consumption of fruit and vegetables for the primary prevention of cardiovascular diseases. Cochrane Database Syst Rev. 2013;6:CD009874.","DOI":"10.1002\/14651858.CD009874.pub2"},{"key":"988_CR48","doi-asserted-by":"crossref","unstructured":"Hooper L, Summerbell CD, Thompson R, Sills D, Roberts FG, Moore HJ, et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev. 2012;5:CD002137.","DOI":"10.1002\/14651858.CD002137.pub3"},{"key":"988_CR49","doi-asserted-by":"crossref","unstructured":"Shaw KA, Gennat HC, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006;4:CD003817.","DOI":"10.1002\/14651858.CD003817.pub3"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-017-0988-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T02:24:29Z","timestamp":1570587869000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-017-0988-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["988"],"URL":"https:\/\/doi.org\/10.1186\/s12916-017-0988-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]},"article-number":"5"}}